Chest
Volume 139, Issue 2, February 2011, Page 472
Journal home page for Chest

Correspondence
The Dilemma of Albuterol Dosing for Acute Asthma Exacerbations in Pediatric Patients

https://doi.org/10.1378/chest.10-2163Get rights and content

Section snippets

To the Editor

Inhaled albuterol is a first-line treatment of acute asthma exacerbations. Nebulized albuterol doses recommended by expert consensus guidelines for exacerbations in children ≤ 12 years of age are “0.15-0.3 mg/kg up to 10 mg every 1-4 hours as needed, or 0.5 mg/kg/hour by continuous nebulization.”1 Although the benefit of continuous treatment is well established, we can find only one, small randomized controlled trial (N = 33) that compared the recommended guideline continuous nebulized

References (4)

  • National Heart, Lung, and Blood Institute

    Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma

    (2007)
  • CA Camargo et al.

    Continuous versus intermittent beta-agonists in the treatment of acute asthma

    Cochrane Database Syst Rev

    (2003)
There are more references available in the full text version of this article.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Moore served in the speaker's bureau for Merck from July 2008 to June 2009. He also received a research grant from Asklepion Pharmaceuticals for a clinical trial of a medication for asthma. Drs Arnold, Moore, and Hartert currently receive National Institutes of Health support for research grants. Dr Abramo has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

© 2011 American College of Chest Physicians Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).

View full text